<DOC>
	<DOCNO>NCT01538680</DOCNO>
	<brief_summary>This phase III B , prospective , interventional , open-label , single-arm , multicenter study provide regorafenib subject diagnose metastatic colorectal cancer fail standard therapy therapy alternative exist , time positive result approval / availability market , collect safety data regorafenib market access . Regorafenib oral ( i.e . take mouth ) multi-targeted kinase inhibitor . A kinase inhibitor target certain key protein essential survival cancer cell . By specifically target protein , regorafenib may stop cancer growth . The growth tumor may decrease prevent specific protein function . The primary endpoint study safety .</brief_summary>
	<brief_title>Regorafenib Subjects With Metastatic Colorectal Cancer ( CRC ) Who Have Progressed After Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Male female subject 18 year age Life expectancy least 3 month Histological cytological documentation adenocarcinoma colon rectum . All histological type exclude . Subjects metastatic colorectal cancer ( Stage IV ) Progression within 3 month follow last administration approve standard therapy must include fluoropyrimidine , oxaliplatin , irinotecan , bevacizumab cetuximab/panitumumab ( KRAS WT ) ( WT : wild type ) ECOG Performance Status â‰¤ 1 ( ECOG : Eastern Cooperative Oncology Group ) Adequate bone marrow , liver renal function Women childbearing potential men must agree use adequate contraception Prior treatment regorafenib Congestive heart failure &gt; /= New York Heart Association ( NYHA ) class 2 Uncontrolled hypertension ( Systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) Any hemorrhage bleeding event &gt; /= CTCAE Grade 3 within 4 week prior start study medication . Persistent proteinuria CTCAE Grade 3 ( &gt; 3.5g/24 hour ) Unresolved toxicity high CTCAE ( v. 4.0 ) Grade 1 attributed prior therapy/procedure exclude alopecia , hypothyroidism oxaliplatin induced neurotoxicity &lt; /= Grade 2 Systemic anticancer therapy include cytotoxic therapy , signal transduction inhibitor , immunotherapy , hormonal therapy trial within 4 week ( within 6 week mitomycin C ) start receive study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>